浙江昭华生物医药

Zhaohua Biotech is a clinical-stage biopharmaceutical company headquartered in Huzhou, China, focused on developing next-generation small molecule drugs for metabolic and chronic diseases. The company's primary focus is on metabolic dysfunction-associated steatohepatitis (MASH/NASH), obesity, and type 2 diabetes. Its lead candidate, ZH-001, is a potent and selective thyroid hormone receptor beta (THR-beta) agonist designed to improve lipid metabolism and reduce liver fat. Zhaohua Biotech was founded by Dr. Zhaohua Li, an expert in metabolic drug discovery with a background in major global pharmaceutical firms. The company has successfully raised significant venture capital to advance its pipeline through clinical trials in both China and international markets.